| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae6da34296d54b648baa249c974b6a1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6826ff00071dac593b2db7bef0f96c0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5406 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 |
| filingDate |
2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7422b4565854fe540e21a09831dd7d6f |
| publicationDate |
2011-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011106779-A1 |
| titleOfInvention |
Use of modified il-4 mutien receptor antagonists to treat dermatitis |
| abstract |
The present invention provides methods for treating atopic diseases, including atopic dermatitis and other inflammatory or allergic skin disorders by administering mutant human Interleukin-4 (IL-4) compositions that act as antagonists to IL 4 and IL-13. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019197510-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3946412-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2882449-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9738696-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11352402-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3553078-A1 |
| priorityDate |
2010-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |